

ATTACHMENT A

SCHEDULE OF DOCUMENTS – FOI 3137

Document No.	Date	Pages	Description	Decision on access ¹	Exemption/s
1	17 August 2021	3	ATAGI COVID-19 Working Group Sub Group 1 – meeting outcomes	RIE	Section 22 Section 47C Section 47E Section 47F
2	18 August 2021	3	ATAGI COVID-19 Adverse Events Following Immunisation meeting outcomes	RIE	Section 22 Section 47C Section 47F
3	20 August 2021	2	ATAGI COVID-19 Working Group Executive meeting outcomes	RIE	Section 22 Section 47C Section 47F
4	25 August 2021	2	ATAGI COVID-19 Working Group Sub Group 2 meeting outcomes	RIE	Section 22 Section 47F
5	27 August 2021	3	ATAGI COVID-19 Working Group Executive meeting outcomes	RIE	Section 22 Section 47F
6	17 August 2021	2	ATAGI statement on the use of COVID-19 vaccines in all young adolescents in Australia	R	Publicly available document

¹ R = Release, RIE = Release with irrelevant and exempt material removed.

**ATAGI COVID-19 Working Group
Vaccine Utilisation and Prioritisation Subgroup Meeting #34
Outcomes – 17 August 2021, 11:30AM-12:30PM**

Attendees:

Sub-group 1 members:

Kristine Macartney (acting lead)
Katie Flanagan
Chris Blyth
Nigel Crawford
James Wood
Jodie McVernon
Penny Burns
Bette Liu
Angus Dawson
Richard Kidd
Kirsten Howard
Tom Snelling

s 47F

Department of Health

s 47F

s 47F

s 22

s 22

3. Broader adolescent program

Members:

- NOTED that advice on an adolescent program builds upon previous advice on prioritised adolescents aged 12-15 years (i.e. those with underlying medical conditions, Aboriginal and Torres Strait Islander people, and those living in remote communities).
- NOTED the advice contains universal recommendations for an adolescent program and covers benefits and risks of vaccination with Pfizer Comirnaty and Moderna Spikevax, as well as programmatic considerations for policy makers
- DISCUSSED the importance of inclusion of information for providers on 16 and 17 year olds
s 47C
- DISCUSSED that advice is influenced by the epidemiological situation and likelihood of outbreaks rather than a disease free population
- NOTED modelling will expand to investigate schools as a special setting in the context of wider epidemiology
- DISCUSSED the UK Joint Committee on Vaccination and Immunisation recommendations of one dose for people under 16-17 until further notice
 - s 47C
- NOTED the ATAGI recommendation is for a complete two-dose course s 47C
s 47C
- NOTED NCIRS will track logistical considerations and pharmacy regulations to inform recommendations on pharmacy delivery of an adolescent vaccine program (e.g. for Spikevax)
- NOTED next steps:
s 47E

s 22

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982
BY THE DEPARTMENT OF HEALTH

ATAGI Meeting: AstraZeneca and TTS

18 August 2021, 1:00 – 2:00pm

In attendance:

Members	NCIRS Technical Staff	Department of Health reps
Chris Blyth	s 47F	s 22
Allen Cheng		Elspeth Kay
Bette Liu		Hope Peisley
Cheryl Jones		John Skerritt
Diane Walsh		Lisa Schofield
James Wood		s 22
Karen Bellamy		
Katherine Gibney		
Katie Flanagan		
Kristine Macartney		s 47F
Kristy Cooper		
Michelle Giles		
Nigel Crawford		
Penny Burns		
Robyn Gibbs		
Tom Snelling		
Tony Korman		
Vanessa Johnston		

s 22

THIS DOCUMENT HAS BEEN RELEASED
 THE FREEDOM OF INFORMATION ACT
 BY THE DEPARTMENT OF HEALTH

ATAGI Meeting: AstraZeneca and TTS

18 August 2021, 1:00 – 2:00pm

s 22

s 22

4. Adolescent Program

Members NOTED and DISCUSSED:

- Summary of SG1 advice on Adolescent Program
- SG1 recommended an Adolescent Program; pros outweigh the cons
- Group's support for the Adolescent Program
- Advice should capture support for adolescent program in context of uptake in currently eligible populations and current supplies
- Lack of modelling data (work on modelling anticipated)
- Logistic of Adolescent Program still being finalised by SG2 (final stages)
- Where do adolescents fit in prioritisation?
- s 47C

s 22

ATAGI Meeting: AstraZeneca and TTS

18 August 2021, 1:00 – 2:00pm

s 22

THIS DOCUMENT HAS BEEN RELEASED
THE FREEDOM OF INFORMATION ACT
BY THE DEPARTMENT OF HEALTH

**Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group
Executive Team Meeting #45 by Videoconference
20 August 2021, 10:30-11:30AM EST
Outcomes**

In attendance:

Executive Members

Chris Blyth
Allen Cheng
Nigel Crawford
Michelle Giles
Katie Flanagan
Robyn Gibbs
Kristine Macartney
Lisa Schofield
Hope Peisley

s 47F

Department of Health representatives

Darius Everett

s 47F

s 47F

s 22

s 22

3. Documents for endorsement

s 22

IS DOCUMENT HAS BEEN RELEASED UNDER
E FREEDOM OF INFORMATION ACT 1982
Y THE DEPARTMENT OF HEALTH

s 22

SG1 advice on a broader adolescent program

Members NOTED:

s 47C

- The SG1 advice would be endorsed s 47C
- Related SG2 advice on the programmatic considerations would be progressed separately and is due for ATAGI endorsement at next week's executive meeting.

Action item	Responsible Officer (s)	Progress
Review SG1 adolescent clinical advice and incorporate into final advice to Government	ATAGI COVID-19 WG Exec	In progress

s 22

s 22

s 47C

THIS DOCUMENT
THE FREEDOM O
BY THE DEPAR

ATAGI COVID Working Group
Subgroup 2, Meeting No. 20
Wednesday, 25 August 2021, 11:30–12:30pm

Members	s 47F	Department of Health
Karen Bellamy – Lead Chris Moy Lena Sanci Lisa Nissen Madeline Hall Scott Brown		s 22 s 47F
Members		

s 22

4. Considerations for implementing a COVID-19 adolescent vaccination program

Members NOTED and DISCUSSED:

- Consent procedures for adolescents
- Co-administration of COVID-19 vaccine with other routine vaccines
- Risks of COVID-19 vaccination
- Communications resources for adolescents (preference for Commonwealth branded resources and share with jurisdictions)
- “Working with Children” requirements

Members **ENDORSED** *Considerations for implementing a COVID-19 adolescent vaccination program*, following updates to the document as discussed at this meeting.

Action	Responsible officer/s	Progress
4.1 Update and finalise <i>Considerations for implementing a COVID-19 adolescent vaccination program</i> , based on discussions at SG2 meeting on 25 August 2021	NCIRS/Secretariat	Complete

s 22

**ATAGI COVID Working Group
Subgroup 2, Meeting No. 20
Wednesday, 25 August 2021, 11:30–12:30pm**

s 22

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982
BY THE DEPARTMENT OF HEALTH

**Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group
Executive Team Meeting #46 by Videoconference
27 August 2021, 2-3PM EST
Outcomes**

In attendance:

Executive Members

Chris Blyth
Allen Cheng
Nigel Crawford
Michelle Giles
Katie Flanagan
Kristine Macartney
Lisa Schofield
Hope Peisley

s 47F

Department of Health representatives

Darius Everett

s 47F

s 47F

1. Meeting opened

Members NOTED:

- Attendees and apologies (Robyn Gibbs)
- Acknowledgement of country
- No new conflicts of interest.

s 22

5. Sub-group issues to raise

Members:

- NOTED further clarity is needed and on who can do media on the adolescent program
- NOTED the adolescents (outside of currently eligible adolescents 12-15) would become eligible to book for vaccination on 13 September 2021
- DISCUSSED vaccine choice for people over the age of 60

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982
BY THE DEPARTMENT OF HEALTH



Australian Government
Department of Health



[Home](#) > [News](#)

ATAGI statement on the use of COVID-19 vaccines in all young adolescents in Australia

Recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI) on COVID-19 vaccines in adolescents.

Date published: 27 August 2021

Type: News

Intended audience: General public



This statement was originally published on 27 August 2021, and has now been updated.

The Australian Technical Advisory Group on Immunisation (ATAGI) has previously recommended that adolescents from 12 years of age belonging to the following groups be prioritised for vaccination using Comirnaty (Pfizer):

- Individuals with specified underlying risk conditions, including NDIS participants
- All Aboriginal and Torres Strait Islander children
- All children in remote communities, as part of broader community outreach vaccination programs.

ATAGI has reviewed the evidence and now supports COVID-19 vaccination in all adolescents from 12 years of age.

Vaccination against COVID-19 is recommended for all people from 12 years of age, extending the current recommendation for those 16 years and older.

A two dose schedule using Pfizer or Spikevax (Moderna) is recommended.

ATAGI has developed these recommendations following careful consideration of the relevant benefits, risks, uncertainties and evidence on this topic, including:

- Safety, efficacy and effectiveness of COVID-19 vaccines in adolescents from clinical trials and overseas vaccination programs
- Epidemiology of COVID-19 in adolescents including disease severity and complications and their role in transmission in the population
- The potential for indirect benefits of vaccination, such as on family and adolescent wellbeing and participation in education
- Evidence of potential acceptance of vaccination in this age group.

ATAGI notes that supply of Pfizer and Moderna remains constrained, and so the timing of inclusion of adolescents in the national COVID-19 vaccination program needs to be balanced against access to vaccine in other populations.

The timing for inclusion of adolescents in the COVID-19 vaccination program may also vary depending on local epidemiology, including outbreaks. It should be noted that there is a delay of 2-3 weeks after receiving a first dose of vaccine to gaining protection from COVID-19.

Further detail regarding this ATAGI recommendation is [available here](#).

Tags:

- Communicable diseases
- Emergency health management
- Immunisation
- Coronavirus (COVID-19)
- COVID-19 vaccines

← **All news**

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982
BY THE DEPARTMENT OF HEALTH